No evidence of JC virus reactivation in natalizumab treated multiple sclerosis patients: An 18 month follow-up study

Journal of Neurology, Neurosurgery and Psychiatry

Volumn 81, Issue 12, 2010, Pages 1345-1350

  Rinaldi, Luciano ^a   Rinaldi, Francesca ^a   Perini, Paola ^a   Calabrese, Massimiliano ^a   Seppi, Dario ^a   Grossi, Paola ^a   Mattisi, Irene ^a   Barzon, Luisa ^a   Mengoli, Carlo ^a   Sanzari, Mariella ^a   Palú, Giorgio ^a   Gallo, Paolo ^a  

^a UNIVERSITY HOSPITAL OF PADOVA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

NATALIZUMAB; VIRUS DNA;

ADULT; ALOPECIA; ARTHRALGIA; ARTICLE; B LYMPHOCYTE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL COUNT; CELL EXPANSION; CHILL; CLINICAL ARTICLE; DRUG INDUCED HEADACHE; EXHAUSTION; FACE RASH; FATIGUE; FEMALE; FEVER; FOLLOW UP; HERPES LABIALIS; HERPES ZOSTER; HUMAN; IMMUNOCOMPETENT CELL; JC VIRUS; LEUKOENCEPHALOPATHY; MALE; MOOD; MOUTH ULCER; MULTIPLE SCLEROSIS; NATURAL KILLER CELL; NAUSEA; NUCLEAR MAGNETIC RESONANCE IMAGING; PLASMA; PNEUMONIA; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PRURITUS; QUALITY OF LIFE; SEIZURE; SIDE EFFECT; SWEATING; T LYMPHOCYTE; TACHYCARDIA; UPPER RESPIRATORY TRACT INFECTION; URINARY TRACT INFECTION; URINE; URTICARIA; VIREMIA; VIRUS REACTIVATION;

EID: 78649628087     PISSN: 00223050     EISSN: 1468330X     Source Type: Journal    
DOI: 10.1136/jnnp.2009.201079     Document Type: Article

References (38)

1. Lutterotti A, Martin R. Getting specific: monoclonal antibodies in multiple sclerosis. Lancet Neurol 2008;7:538-47.
2. Yednock TA, Cannon C, Fritz LC, et al. Prevention of experimental autoimmune encephalomyelitis by antibodies against alpha 4 beta 1 integrin. Nature 1992;356:63-6.
3. Polman CH, O'Connor PW, Havrdova E, et al. A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med 2006;354:899-910.
4. Rudick RA, Stuart WH, Calabresi PA, et al. Natalizumab plus interferon beta-1a for relapsing multiple sclerosis. N Engl J Med 2006;354:911-23.
5. Clifford DB. Natalizumab and PML: a risky business? Gut 2008;57:1347-9.
6. Hou J, Major EO. Progressive multifocal leukoencephalopathy: JC virus induced demyelination in the immune compromised host. J Neurovirol 2000;6(Suppl 2): S98-100.
7. Kleinschmidt-DeMasters BK, Tyler KL. Progressive multifocal leukoencephalopathy complicating treatment with natalizumab and interferon beta-1a for multiple sclerosis. N Engl J Med 2005;353:369-74.
8. Langer-Gould A, Atlas SW, Green AJ, et al. Progressive multifocal leukoencephalopathy in a patient treated with natalizumab. N Engl J Med 2005;353:375-81.
9. Kappos L, Bates D, Hartung HP, et al. Natalizumab treatment for multiple sclerosis: recommendations for patient selection and monitoring. Lancet Neurol 2007;6:431-41.
10. Krumbholz M, Pellkofer H, Gold R, et al. Delayed allergic reaction to natalizumab associated with early formation of neutralizing antibodies. Arch Neurol 2007;64:1331-3.
11. Leussink VI, Lehmann HC, Hartung HP, et al. Type III systemic allergic reaction to natalizumab. Arch Neurol 2008;65:851-2.
12. Chen Y, Bord E, Tompkins T, et al. Asymptomatic reactivation of JC virus in patients treated with natalizumab. N Engl J Med 2009;361:1067-74.
13. Miller DH, Khan OA, Sheremata WA, et al. A controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med 2003;348:15-23.
14. Bonig H, Wundes A, Chang KH, et al. Increased numbers of circulating hematopoietic stem/progenitor cells are chronically maintained in patients treated with the CD49d blocking antibody natalizumab. Blood 2008;111:3439-41.
15. Zohren F, Toutzaris D, Klarner V, et al. The monoclonal anti-VLA-4 antibody natalizumab mobilizes CD34+ hematopoietic progenitor cells in humans. Blood 2008;111:3893-5.
16. Krumbholz M, Meinl I, Kumpfel T, et al. Natalizumab disproportionately increases circulating pre-B and B cells in multiple sclerosis. Neurology 2008;71:1350-4.
17. Polman CH, Reingold SC, Edan G, et al. Diagnostic criteria for multiple sclerosis: 2005 revisions to the "McDonald Criteria". Ann Neurol 2005;58:840-6.
18. Gold R, Jawad A, Miller DH, et al. Expert opinion: guidelines for the use of natalizumab in multiple sclerosis patients previously treated with immunomodulating therapies. J Neuroimmunol 2007;187:156-8.
19. Kurtzke JF. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 1983;33:1444-52.
20. Royer RJ, Benichou C. International reporting of adverse drug reactions. Final report of CIOMS ADR Working Group. Therapie 1991;46:173-8.
21. Rinaldi L, Gallo P, Calabrese M, et al. Longitudinal analysis of immune cell phenotypes in early stage multiple sclerosis: distinctive patterns characterize MRI-active patients. Brain 2006;129:1993-2007.
22. Rao SM, Leo GJ, Bernardin L, et al. Cognitive dysfunction in multiple sclerosis. I. Frequency, patterns, and prediction. Neurology 1991;41:685-91.
23. Calabrese M, De Stefano N, Atzori M, et al. Detection of cortical inflammatory lesions by double inversion recovery magnetic resonance imaging in patients with multiple sclerosis. Arch Neurol 2007;64:1416-22. (Pubitemid 47572665)
24. Havrdova E, Galetta S, Hutchinson M, et al. Effect of natalizumab on clinical and radiological disease activity in multiple sclerosis: a retrospective analysis of the Natalizumab Safety and Efficacy in Relapsing-Remitting Multiple Sclerosis (AFFIRM) study. Lancet Neurol 2009;8:254-60.
25. Andreoletti L, Lescieux A, Lambert V, et al. Semiquantitative detection of JCV-DNA in peripheral blood leukocytes from HIV-1-infected patients with or without progressive multifocal leukoencephalopathy. J Med Virol 2002;66:1-7.
26. Dubois V, Moret H, Lafon ME, et al. Prevalence of JC virus viraemia in HIV-infected patients with or without neurological disorders: a prospective study. J Neurovirol 1998;4:539-44.
27. Pineton de Chambrun G, Vernier-Massouille G, Viget N, et al. Is detection of JC virus DNA in blood a valuable screening test for progressive multifocal leukoencephalopathy in Crohn's disease patients eligible for anti-alpha4 integrin therapy? Gut 2008;57:1633-4.
28. Verbeeck J, Van Assche G, Ryding J, et al. JC viral loads in patients with Crohn's disease treated with immunosuppression: can we screen for elevated risk of progressive multifocal leukoencephalopathy? Gut 2008;57:1393-7.
29. Kitamura T, Aso Y, Kuniyoshi N, et al. High incidence of urinary JC virus excretion in nonimmunosuppressed older patients. J Infect Dis 1990;161:1128-33.
30. Markowitz RB, Thompson HC, Mueller JF, et al. Incidence of BK virus and JC virus viruria in human immunodeficiency virus-infected and -uninfected subjects. J Infect Dis 1993;167:13-20.
31. Varnier OE, McDermott JL, Giacomazzi CG, et al. Non invasive surveillance of JCV reactivation in blood and urine from natalizumab treated MS patients, blood donors, and immunocompromised patients identifies two PML cases in HIV and congenital immunodeficiency patients. Mult Scler 2009;15:S276.
32. Lindå H, von Heijne A, Major EO, et al. Progressive multifocal leukoencephalopathy after natalizumab monotherapy. N Engl J Med 2009;361:1081-7.
33. Sadiq SA, Puccio LM, Brydon EW. JCV detection in multiple sclerosis patients treated with natalizumab. J Neurol. Published Online First: 7 January 2010. doi: 10.1007/s00415-009-5444-4.
34. Ransohoff RM. Natalizumab for multiple sclerosis. N Engl J Med 2007;356:2622-9.
35. Azzi A, De Santis R, Ciappi S, et al. Human polyomaviruses DNA detection in peripheral blood leukocytes from immunocompetent and immunocompromised individuals. J Neurovirol 1996;2:411-16.
36. Monaco MC, Atwood WJ, Gravell M, et al. JC virus infection of hematopoietic progenitor cells, primary B lymphocytes, and tonsillar stromal cells: implications for viral latency. J Virol 1996;70:7004-12. (Pubitemid 26307415)
37. Tornatore C, Berger JR, Houff SA, et al. Detection of JC virus DNA in peripheral lymphocytes from patients with and without progressive multifocal leukoencephalopathy. Ann Neurol 1992;31:454-62.
38. Major EO. Reemergence of PML in natalizumab-treated patients-new cases, same concerns. N Engl J Med 2009;361:1041-3.